News & blog

Knutsford-based Crawford secures Canadian exclusivity deal

Wound-care company Crawford Healthcare has signed a new deal with Canada-based Exciton Technologies to strengthen its place in the global healthcare market.

The agreement will see the rights for advanced materials developer Exciton’s silver oxysalt technology, designed for antimicrobial wound treatment, awarded to Crawford Healthcare.

While Crawford has been working with Exciton under licence for the last three years, the company moved to sign a global exclusivity agreement following what it called a “dramatic market response” to the use of the patented technology in the UK and US.

Read more